Thalidomide for acute treatment of neurosarcoidosis

E. R. Hammond, A. I. Kaplin, D. A. Kerr

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Study design: Case report. Clinical setting: Johns Hopkins University School of Medicine, Baltimore, MD, USA. Case report: Sarcoidosis is a multi-system granulomatous disease of unknown etiology with worldwide distribution. The involvement of the nervous system is common - neurosarcoidosis. Immune responses play an important role in the inflammatory process and granuloma formation. We report a case of neurosarcoidosis that was refractory to two courses of intravenous steroids. Upon initiation of oral thalidomide, the patient showed dramatic improvement clinically and on magnetic resonance imaging. Conclusion: Thalidomide is an immunomodulatory agent that acts to inhibit production of tumor-necrosis factor-α (TNF-α), an important mediator in CNS inflammation, by enhancing TNF-α mRNA degradation. Corticosteroids have been the mainstay of treatment of neurosarcoidosis with success at halting progression of the immune process in 50% cases. Thalidomide offers unique opportunities at managing CNS inflammation due to neurosarcoidosis. Disclosures: None.

Original languageEnglish (US)
Pages (from-to)802-803
Number of pages2
JournalSpinal Cord
Issue number12
StatePublished - Dec 2007


  • Immunotherapy
  • Neurosarcoidosis
  • Thalidomide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Thalidomide for acute treatment of neurosarcoidosis'. Together they form a unique fingerprint.

Cite this